Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: ASE
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Starpharma Holdings Ltd

+ Add to Watchlist

SPL:AU

0.4600 AUD 0.0150 3.37%

As of 00:10:21 ET on 01/29/2015.

Snapshot for Starpharma Holdings Ltd (SPL)

Open: 0.4450 Day's Range: 0.4350 - 0.4600 Volume: 172,746
Previous Close: 0.4450 52wk Range: 0.4100 - 0.9850 1-Yr Rtn: -42.14%

Stock Chart for SPL

No chart data available.
  • SPL:AU 0.4600
  • 1D
  • 1M
  • 1Y
0.4450
Interactive SPL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SPL

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. AS51 -
Earnings Per Share (AUD) (ttm) -0.0500
Est. EPS (AUD) (06/2015) -0.0350
Est. PEG Ratio -
Market Cap (M AUD) 146.80
Shares Outstanding (M) 319.14
30 Day Average Volume 386,780
Price/Book (mrq) 3.9802
Price/Sale (ttm) 488.6920
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SPL

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for SPL

Starpharma Holdings Limited is biotechnology company involved in the research, development and commercialization of dendrimer-based for pharmaceutical, life sciences and other applications. The Company's lead product in development is VivaGel, a microbicide gel for women, for the prevention and treatment of bacterial vaginosis adn a range of sexually transmitted diseases.

Robert Bain Thomas "Rob"ChairmanJacinth K Fairley "Jackie"CEO/Executive Director
Nigel J BaadeCFO/SecretaryTony EglezosVP:Business Development
More Company Profile & Key Executives for SPL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement

Press Releases for SPL

Advertisement
Sponsored Links
Advertisements
sec ||= nil